RESEARCH USE ONLY - Not for human or veterinary use. Supplied for lawful in vitro research and qualified laboratory investigation only. QUALITY - Peptide catalogue items are specified at ≥99% purity with batch documentation. Store lyophilised powders as directed before reconstitution. COMPLIANCE - You are responsible for lawful purchase, possession, and use in your jurisdiction, including institutional and safety requirements. SAFE HANDLING - Use trained personnel, appropriate PPE, and aseptic technique. Do not ingest, inject, or use outside a controlled research setting. POLICIES & ORDERS - Shipping, returns, and research-use terms apply to every order. Read our Research Use Policy and footer legal links before buying.
Home Products IGF-1 LR3
IGF-1 LR3 0.1mg lyophilised vial - for research purposes only
Purity
≥99%
Format
Lyophilised
Size
0.1mg
Storage
−20°C
Growth factor · Metabolic research

IGF-1 LR3 — Long R3 IGF-1

Insulin-like growth factor-I Long R3 analogue · 0.1mg lyophilised

≥99% Purity
CoA on release

IGF-1 LR3 is a recombinant analogue with an N-terminal extension and arginine substitution at position 3, extending half-life in many in-vitro systems. It is used in research on growth-factor signalling, protein synthesis pathways, and metabolic cell models - not for human use.

Size - 0.1mg

Supplied as 0.1mg lyophilised peptide per vial (single presentation).

£39.99
View Cart →

What is IGF-1 LR3?

IGF-1 LR3 (Insulin-like Growth Factor-I Long Arg3) is a recombinant analogue of IGF-1 engineered with an N-terminal extension and an arginine substitution at position 3. These changes reduce binding to most circulating IGF-binding proteins (IGFBPs) and extend biological half-life in many cell-based and in-vitro systems compared with native IGF-1.

Like native IGF-1, LR3 engages the type-1 IGF receptor (IGF-1R) and downstream PI3K/AKT and MAPK cascades that regulate growth, survival, and metabolic gene programmes. Laboratories use it as a potent, defined ligand when studying muscle cell hypertrophy signalling, nutrient-sensing pathways, and cross-talk with insulin receptor hybrids - always under appropriate biosafety and ethics frameworks.

Optimus Peptides supplies IGF-1 LR3 solely for qualified research. It is not a therapeutic product and must not be used in humans or animals outside legally approved research programmes.

Product Code
IGF-1 LR3
Receptor Target
IGF-1R (primary)
Approx. Molecular Mass
~9.1 kDa
Presentation
0.1mg lyophilised vial
Research Focus
GH axis · growth signalling · metabolism

Research Background

IGF-1 LR3 is widely cited in in-vitro pharmacology because its prolonged receptor engagement simplifies chronic stimulation designs that would be impractical with unmodified IGF-1. Common research themes include:

  • Myotube and satellite-cell models of protein synthesis, hypertrophy, and atrophy-rescue readouts.
  • Metabolic cell lines examining glucose uptake, lipogenesis, and mitochondrial coupling.
  • Receptor pharmacology: IGF-1R vs insulin receptor selectivity, hybrid receptor signalling, and pathway knockout rescues.
  • Cancer biology models where IGF axis inhibition or stimulation is studied (highly controlled environments; institutional oversight required).

Research Applications

  • Defined-serum replacement experiments requiring consistent IGF-1R drive
  • Co-culture and organoid systems where growth-factor gradients are titrated
  • Comparative ligand panels alongside native IGF-1 or other IGF-axis peptides

Literature potency and stability data are assay-dependent. Always titrate for your specific model and readout.

Technical Specifications

Appearance
White lyophilised powder
Purity
≥99% (HPLC specification)
Format
Lyophilised (freeze-dried)
Net Mass
0.1mg peptide per vial (label)
Reconstitution
Acidified sterile buffer or protocol-specific diluent
Storage (Lyophilised)
−20°C, protect from light and moisture
Storage (Reconstituted)
−20°C or −80°C aliquots; minimise freeze–thaw
Shelf Life
Refer to batch label (lyophilised)
CoA
Available on request per batch

Frequently Asked Questions

Why is the vial only 0.1mg?

IGF-1 LR3 is extremely potent on a mass basis in many cell assays. Microgram-scale vials reduce waste and allow precise dilution into working stocks aligned with typical in-vitro dose ranges.

How does LR3 differ from native IGF-1?

LR3 incorporates structural changes that weaken IGFBP binding in serum-containing systems and extend functional half-life, making chronic stimulation protocols easier to control in culture - always validate in your own matrix.

What biosafety considerations apply?

Treat as a bioactive growth factor. Use appropriate PPE, aseptic handling, institutional IBC guidance where applicable, and secure storage. Do not aerosolise or pipette by mouth.

Is a Certificate of Analysis available?

Yes. Request batch-specific CoA documentation when you order or quote your batch number after purchase.

Related products

Tesamorelin5mg
GH axis
Tesamorelin

GHRH analogue - pituitary GH dynamics research.

Out of stock
CJC-12955mg
GH axis
CJC-1295

GHRH(1-29) analogue without DAC.

Out of stock